View Clinical Trial (Medical Research Study)
Biomarkers of Molecular Risk in Smokers
| City: |
|
New York |
| State: |
|
New York |
| Zip Code: |
|
10065 |
| Conditions: |
|
Smoking Cessation |
| Purpose: |
|
Doctors at MSKCC are doing this research study to see if smokers are interested in the idea
that genes might be markers of cancer risk, and to see if smokers would want to learn this
information about their risk if it were available.
Different versions of the gene called UGT1A7 are found in different people. Certain versions
of this gene can increase the risk of cancer in people. In this study, doctors will
determine the different types of UGT1A7 in smokers and find out whether smokers show good
interest and understanding. The information from this study will be used in future studies
to identify smokers at increased risk for cancer, and to help smokers quit.
|
| Study Summary: |
|
This study consists of two arms; both of which are observational studies of molecular
assessments of risk for tobacco related cancer. Arm A of the protocol is a pilot
crosssectional study that evaluates the feasibility of obtaining and testing a genetic
marker of cancer susceptibility (UGT1A7 polymorphisms) in smokers. It also explores smokers'
interest in and comprehension of genetic risk assessments as possible tools for increasing
motivation for smoking cessation. The second arm of this protocol, Arm B, is an
observational prospective evaluation of a putative noninvasive biomarker of tobacco smoke
exposure - urinary prostaglandin E-metabolite (PGE-M) - in smokers motivated to reduce
and/or cease smoking.
|
| Criteria: |
|
Inclusion Criteria:
- Arm A
- 18 years or older;
- >5 packyear history of smoking;
- Ability to understand and sign informed consent.
- Arm B
- 18 years or older;
- >10 packyear history of smoking;
- Intention to taper and/or quit smoking within 6 months
- Ability to understand and sign informed consent.
Exclusion Criteria:
- Arm A
- Diagnosis of any cancer in the preceding twelve months; (excluding non melanoma skin
cancer).
- Arm B
- Diagnosis of any cancer in the preceding twelve months; (excluding non melanoma skin
cancer).
- Use of any COX-2 inhibitor, steroid, or non-steroidal anti-inflammatory medication
(excluding cardioprotective aspirin > 81mg/d) within one week of urine collection
|
| NCT ID: |
|
NCT00598143 |
| Primary Contact: |
|
Principal Investigator
Jay Boyle, MD
Memorial Sloan-Kettering Cancer Center
Jay Boyle, MD
Phone: 212-639-2906
|
| Backup Contact: |
|
Jamie Ostroff, PhD
Phone: 646-888-0041
|
| Location Contact: |
|
New York, New York 10065
United States
Jay Boyle, MD
Phone: 212-639-2906
Site Status: Recruiting |
| Data Source: |
|
ClinicalTrials.gov |
| Date Processed: |
|
May 22, 2013 |
| Modifications to this listing: |
|
Only selected fields are shown, please use the link
below to view all information about this clinical trial. |
|
Click to view Full Listing
|